Compare Prudential Financial Inc (PRU) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential Financial Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Prudential Financial Inc trades at $117.62 (market cap $41.19B), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: Prudential Financial Inc pays a 4.69% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| PRU | XBI | |
|---|---|---|
Market Cap | $41.19B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $125.13 | $169.55 |
52-Week Low | $92.00 | $93.43 |
Enterprise Value | $69.96B | — |
Dividend Yield | 4.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PRU trades at $119.38, down 2.16% today, with a neutral technical outlook and mixed earnings history. The stock shows strong profitability with a 6.04% net margin and 12.46% ROE, while valuation metrics like a P/E of 10.82 and P/S of 0.64 appear attractive. Recent news highlights PGIM's ETF launches and conference participation, signaling strategic focus.
The outlook is cautious; analyst consensus is a Hold with a $113.20 target below the current price. Risks include volatile cash flows and high leverage, but steady dividends and earnings beats offer support. Upside depends on execution of cost reductions and capital-light growth amid economic uncertainty.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
